Stephen Thorne

Stephen Thorne is a distinguished expert in the field of cancer immunotherapy, boasting a comprehensive background that spans over 15 years in both research and leadership roles. With a focus on pre-clinical and translational development, he has dedicated his career to pioneering novel cancer immunotherapies, including immune cell based therapies, oncolytic viral therapies, and gene therapy. Thorne's expertise extends to working with immunocompetent mouse cancer models and employing non-invasive molecular imaging techniques in animal models. His experience also includes process development for intricate biological therapies, as well as the creation of immune monitoring and immune assays.

Stephen Thorne pursued his academic journey by earning a Doctor of Philosophy (Ph.D.) in Microbiology from Imperial College London, and a Bachelor of Applied Science (B.A.Sc.) in Biochemistry from Oxford University. His educational background has equipped him with a solid foundation to excel in the complex and dynamic field of cancer immunotherapy.

Throughout his career, Stephen Thorne has held key positions in various esteemed organizations. Currently, he serves as the Chief Scientific Officer at KaliVir Immunotherapeutics, a role that allows him to drive innovation and lead cutting-edge research initiatives in the realm of immunotherapy. Previously, he contributed as a Board Member at Duo Oncology and held the position of Chief Scientific Officer at Western Oncolytics Ltd. Thorne's valuable expertise was further honed during his tenure as a Research Associate at Stanford University and as a PostDoc at Cancer Research UK. Additionally, he served as an Assistant Professor at the University of Pittsburgh, where he imparted knowledge and guidance to future professionals in the field.